Engineering the Immune Synapse: Redefining How We Activate Anti-Tumor Immunity

Session details:

Advances in T-cell engagers, TCR biology, and engineered cell therapies are providing new insights into the immune synapse—the critical interface between immune cells and their targets. Rather than relying on first-generation CD3 engagement alone, next-generation approaches are engineering this interaction through optimized binding, signaling domains, co-stimulation, and immune cell selection to improve efficacy while reducing toxicity. Discussion Points

• What have we learned from first-generation CD3 engagers about immune synapse biology?
• How can we engineer the immune synapse to improve efficacy while minimizing toxicity?
• How are advances in T-cell engagers, TCR biology, and cell therapy informing one another?
• Which engineering strategies—including signaling domains, binding affinity, co-stimulation, and immune cell selection—hold the greatest promise?
• What will define the next generation of immune engagement beyond traditional CD3 targeting?